Development of vaccines for influenza using an immuno-modulator adjuvant and multi-platform approach
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00044
- Awardee
-
The University Of Chicago UEI ZUE9HKT2CLC9
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $9,302,980
Award facts
- Opportunity
-
- 75N93022R00009 Solicitation number
- Contract value 100% obligated
- $9,302,980.38 Current and potential, with all options
- Completion date 62% complete
- Current and potential, with all options
- NAICS code
- 541512 Computer Systems Design Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 24 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Chicago, IL 60637, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $2,021,930 | |
| Other Administrative Action | $0 | |
| Change Order | $1,624,291 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $1,500,000 | |
| Exercise an Option | $2,191,826 | |
| Original award | $1,964,933 |
About this award
The National Institute of Allergy and Infectious Diseases awarded a $9.3 million definitive contract to The University of Chicago for development of vaccines for influenza using an immuno-modulator adjuvant and multi-platform approach on September 30, 2023, with ultimate completion on September 29, 2028.
Place of performance is Chicago, Illinois. The originating work focuses on developing a new adjuvanted vaccine formulation that activates and limits innate immune response. The project targets optimization of a lead compound, PME-564, in combination with well-characterized toll-like receptor agonists to reduce systemic inflammation and associated side effects while boosting antibody responses. Deliverables include identification of optimized vaccine formulations paired with high-performing vaccine platforms and preclinical testing in mice to identify candidates for Phase I transition. The approach addresses a limitation in current adjuvant technology by directly targeting the NF-kappa-B and interferon regulatory factor pathways that generate excessive inflammatory cytokine production, particularly TNF-alpha and IL-6.
The contract is priced firm fixed price with no set-aside. Subcontractors include Inimmune Corp and Valjuvant Corporation, both providing vaccine adjuvant development and formulation services supporting compound synthesis, liposome and emulsion formulation generation, and compatibility testing across multiple vaccine platforms including quadrivalent flu vaccines, mRNA vaccines, and H5N1 pandemic preparedness applications.
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Valjuvant Corporation | $975,341 | |
| Inimmune Corp | $1,003,536 | |
| Valjuvant Corporation | $500,000 |
Quick answers
Who was awarded contract 75N93023C00044?
75N93023C00044 was awarded to The University Of Chicago by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2023.
How much is contract 75N93023C00044 worth?
The government has obligated $9,302,980 on 75N93023C00044.
Was contract 75N93023C00044 competed?
The extent of competition for 75N93023C00044 was full and open competition. The government received 24 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award